Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension
Status:
Withdrawn
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the blood pressure lowering effect and safety of LCZ696 when given alone and in
combination with amlodipine in patients with essential hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine LCZ 696 Sacubitril and valsartan sodium hydrate drug combination